3271---Tianjin Cancer Hospital
Welcome,         Profile    Billing    Logout  
 14 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tong, Zhongsheng
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Not yet recruiting
3
332
RoW
TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Triple Negative Breast Cancer
07/22
07/22
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
256
US, RoW
Afuresertib, Fulvestrant, Afuresertib/placebo
Laekna Limited
Breast Cancer
10/26
12/26
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer
Active, not recruiting
3
466
Europe, Canada, Japan, US, RoW
tucatinib, ONT-380, placebo, T-DM1, Kadcyla
Seagen, a wholly owned subsidiary of Pfizer, Seagen Inc., Seattle Genetics, Inc., Seagen Inc
HER2-positive Breast Cancer
06/23
10/27
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Completed
3
275
RoW
GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant
Genor Biopharma Co., Ltd.
Locally Advanced or Metastatic Breast Cancer
12/22
03/24
NCT05871918: A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

Recruiting
3
832
RoW
TCbHP VS ddEC-THP
Tianjin Medical University Cancer Institute and Hospital
HER-2 Positive Breast Cancer
12/23
12/23
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting
3
350
RoW
GB491 combined with Letrozole, Placebo combined with Letrozole
Genor Biopharma Co., Ltd.
Breast Cancer
01/26
01/27
OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting
2/3
549
Europe, RoW
Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or Metastatic Breast Cancer
02/24
12/25
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Recruiting
2/3
450
RoW
B013+Nab-Paclitaxel
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Triple Negative Breast Cancer (TNBC)
06/25
12/26
NCT04907344: Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Not yet recruiting
2/3
420
RoW
Camrelizumab, Nab-Paclitaxel, Carboplatin
Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer
06/25
06/25
NCT04733417: A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Active, not recruiting
2
35
RoW
SHR6390, famitinib
Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd.
Advanced Breast Cancer, Metastatic Breast Cancer
08/22
09/23
NCT04988165: Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine

Recruiting
2
30
RoW
Traditional Chinese Medicine
Tianjin Medical University Cancer Institute and Hospital
Diarrhea Caused by Antitumor Drugs
10/22
10/22
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Active, not recruiting
2
133
RoW
TJ107 +Pembrolizumab
TJ Biopharma Co., Ltd.
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
06/24
12/24
NCT05560334: A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Recruiting
2
20
RoW
Pemigatinib Pill, Pemazyre
Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
09/24
09/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
PM8002-B004C-TNBC-R, NCT05918133: A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Active, not recruiting
1/2
42
RoW
PM8002, nab-paclitaxel
Biotheus Inc.
TNBC
10/26
10/26
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting
1
150
RoW
SPH5030 tablets
Shanghai Pharmaceuticals Holding Co., Ltd
HER2-positive Advanced Solid Tumors
12/25
12/25
NCT04526028: Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Recruiting
N/A
612
RoW
Fulvestrant Injectable Product, Palbociclib
Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Fulvestrant, Palbociclib
02/23
05/23
Chen, Yajun
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tong, Zhongsheng
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Not yet recruiting
3
332
RoW
TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Triple Negative Breast Cancer
07/22
07/22
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
256
US, RoW
Afuresertib, Fulvestrant, Afuresertib/placebo
Laekna Limited
Breast Cancer
10/26
12/26
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer
Active, not recruiting
3
466
Europe, Canada, Japan, US, RoW
tucatinib, ONT-380, placebo, T-DM1, Kadcyla
Seagen, a wholly owned subsidiary of Pfizer, Seagen Inc., Seattle Genetics, Inc., Seagen Inc
HER2-positive Breast Cancer
06/23
10/27
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Completed
3
275
RoW
GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant
Genor Biopharma Co., Ltd.
Locally Advanced or Metastatic Breast Cancer
12/22
03/24
NCT05871918: A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

Recruiting
3
832
RoW
TCbHP VS ddEC-THP
Tianjin Medical University Cancer Institute and Hospital
HER-2 Positive Breast Cancer
12/23
12/23
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting
3
350
RoW
GB491 combined with Letrozole, Placebo combined with Letrozole
Genor Biopharma Co., Ltd.
Breast Cancer
01/26
01/27
OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting
2/3
549
Europe, RoW
Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or Metastatic Breast Cancer
02/24
12/25
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Recruiting
2/3
450
RoW
B013+Nab-Paclitaxel
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Triple Negative Breast Cancer (TNBC)
06/25
12/26
NCT04907344: Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Not yet recruiting
2/3
420
RoW
Camrelizumab, Nab-Paclitaxel, Carboplatin
Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer
06/25
06/25
NCT04733417: A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Active, not recruiting
2
35
RoW
SHR6390, famitinib
Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd.
Advanced Breast Cancer, Metastatic Breast Cancer
08/22
09/23
NCT04988165: Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine

Recruiting
2
30
RoW
Traditional Chinese Medicine
Tianjin Medical University Cancer Institute and Hospital
Diarrhea Caused by Antitumor Drugs
10/22
10/22
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Active, not recruiting
2
133
RoW
TJ107 +Pembrolizumab
TJ Biopharma Co., Ltd.
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
06/24
12/24
NCT05560334: A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Recruiting
2
20
RoW
Pemigatinib Pill, Pemazyre
Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
09/24
09/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
PM8002-B004C-TNBC-R, NCT05918133: A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Active, not recruiting
1/2
42
RoW
PM8002, nab-paclitaxel
Biotheus Inc.
TNBC
10/26
10/26
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting
1
150
RoW
SPH5030 tablets
Shanghai Pharmaceuticals Holding Co., Ltd
HER2-positive Advanced Solid Tumors
12/25
12/25
NCT04526028: Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Recruiting
N/A
612
RoW
Fulvestrant Injectable Product, Palbociclib
Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Fulvestrant, Palbociclib
02/23
05/23
Chen, Yajun
No trials found

Download Options